Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Zai Lab Ltd Stock Research

ZLAB

25.33USD-0.45(-1.75%)Market Closed
Watchlist

Market Summary

USD25.33-0.45
Market Closed
-1.75%

ZLAB Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

ZLAB Stock Price

ZLAB RSI Chart

ZLAB Valuation

Market Cap

24.5B

Price/Earnings (Trailing)

-62.43

Price/Sales (Trailing)

97.43

EV/EBITDA

-61.65

Price/Free Cashflow

-64.57

ZLAB Price/Sales (Trailing)

ZLAB Profitability

Operating Margin

65.51%

EBT Margin

-177.42%

Return on Equity

-40.95%

Return on Assets

-35.04%

Free Cashflow Yield

-1.55%

ZLAB Fundamentals

ZLAB Revenue

Revenue (TTM)

251.8M

Revenue Y/Y

42.94%

Revenue Q/Q

9.66%

ZLAB Earnings

Earnings (TTM)

-393.0M

Earnings Y/Y

12.35%

Earnings Q/Q

-146%

Price Action

52 Week Range

20.9849.81
(Low)(High)

Last 7 days

-4.6%

Last 30 days

11.5%

Last 90 days

-1.7%

Trailing 12 Months

-45.5%

ZLAB Financial Health

Current Ratio

8.61

ZLAB Investor Care

Shares Dilution (1Y)

1.14%

Diluted EPS (TTM)

-0.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ZLAB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-17
Edmondson Frazor Titus III
acquired
-
-
4,850
chief legal officer
2023-08-17
Edmondson Frazor Titus III
sold (taxes)
-27,623
23.39
-1,181
chief legal officer
2023-08-15
Smiley Joshua L
acquired
-
-
15,900
see remarks
2023-08-15
Smiley Joshua L
sold (taxes)
-107,226
24.52
-4,373
see remarks
2023-06-29
DIEKMAN JOHN D
acquired
499,984
26.45
18,903
-
2023-06-29
Morrison Scott W
acquired
499,984
26.45
18,903
-
2023-06-29
Lis William
acquired
499,984
26.45
18,903
-
2023-06-29
Du Ying
acquired
1,901,230
26.45
71,880
chairperson & ceo
2023-06-29
MOULDER LEON O JR
acquired
499,984
26.45
18,903
-
2023-06-29
Chen Kai-Xian
acquired
499,984
26.45
18,903
-

1–10 of 50

Which funds bought or sold ZLAB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-07
Triatomic Management LP
new
-
360,490
360,490
0.37%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-121,660
610,060
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
sold off
-100
-895,492
-
-%
2023-08-21
OSAIC HOLDINGS, INC.
unchanged
-
-757
3,831
-%
2023-08-16
National Pension Service
sold off
-100
-825,002
-
-%
2023-08-16
Nuveen Asset Management, LLC
reduced
-42.19
-2,085,900
1,941,100
-%
2023-08-15
Regal Partners Ltd
sold off
-100
-1,586,470
-
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
new
-
367,672
367,672
-%
2023-08-15
WELLS FARGO & COMPANY/MN
sold off
-100
-765
-
-%
2023-08-15
GOLDMAN SACHS GROUP INC
reduced
-55.29
-3,985,340
2,368,450
-%

1–10 of 44

Latest Funds Activity

Are funds buying ZLAB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ZLAB
No. of Funds

Schedule 13G FIlings of Zai Lab

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
qiming venture partners iv, l.p.
8.1%
79,229,320
SC 13G/A
Feb 13, 2023
capital world investors
0.6%
5,701,440
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 06, 2023
wellington management group llp
0.00%
0
SC 13G/A
Jul 05, 2022
baillie gifford & co
4.79%
46,935,800
SC 13G/A
Feb 14, 2022
qiming venture partners iv, l.p.
8.2%
7,922,932
SC 13G/A
Feb 14, 2022
du ying
4.78%
4,742,042
SC 13G/A
Feb 14, 2022
invesco ltd.
7.6%
7,286,493
SC 13G
Feb 11, 2022
capital world investors
5.5%
5,294,950
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

Recent SEC filings of Zai Lab

View All Filings
Date Filed Form Type Document
Sep 08, 2023
144
Notice of Insider Sale Intent
Aug 21, 2023
4
Insider Trading
Aug 21, 2023
4
Insider Trading
Aug 17, 2023
4
Insider Trading
Aug 07, 2023
10-Q
Quarterly Report
Aug 07, 2023
8-K
Current Report
Jul 17, 2023
3
Insider Trading
Jul 14, 2023
F-6EF
F-6EF
Jul 06, 2023
8-K
Current Report
Jun 30, 2023
4
Insider Trading

Zai Lab News

Best Stocks
Cantor Fitzgerald Analyst Expresses Positive Outlook on Zai Labs ....
Best Stocks,
42 hours ago
InvestorsObserver
Investing.com UK
The Motley Fool
InvestorsObserver
Investing.com UK
Zacks Investment Research

Returns for ZLAB

Cumulative Returns on ZLAB

5.3%


5-Year Cumulative Returns

-31.6%


3-Year Cumulative Returns

Risks for ZLAB

What is the probability of a big loss on ZLAB?

86.9%


Probability that Zai Lab stock will be more than 20% underwater in next one year

57.7%


Probability that Zai Lab stock will be more than 30% underwater in next one year.

41.9%


Probability that Zai Lab stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZLAB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zai Lab was unfortunately bought at previous high price.

Drawdowns

Financials for Zai Lab

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Revenue9.0%251,802,000231,114,000215,040,000196,611,000182,174,000170,933,000144,312,000115,235,00086,783,00060,843,00048,958,00038,509,26828,778,00023,710,66712,985,00019,678,9286,840,000-
  S&GA Expenses1.7%269,009,000264,490,000258,971,000256,524,000248,971,000239,984,000218,831,000190,220,000159,092,000128,436,000111,312,00093,370,19283,194,00079,248,00070,211,00057,349,12443,907,01621,576,000
  R&D Expenses3.8%291,624,000281,026,000286,408,000391,548,000347,168,000423,308,000573,306,000463,782,000466,738,000392,821,000222,711,000192,244,437185,342,000156,046,667142,221,000213,700,706222,611,160120,278,000
EBITDA100.0%--401,165,000-434,838,000-584,637,000-520,108,000-545,684,000-696,927,000---448,960,000-264,084,000-233,841,429-235,428,000-208,213,333-191,012,000-254,116,806-252,739,328-137,385,223
EBITDA Margin100.0%--1.74-2.02-2.97-2.86-3.19-4.83---7.38-5.39-6.07-8.18-8.78-14.71-12.91-36.95-
Interest Expenses-----------181,000236,508270,000286,667293,000208,182110,39640,000
Earnings Before Taxes4.2%-392,998,000-410,036,000-443,065,000-592,612,000-527,494,000-552,482,000-703,414,000-568,197,000-535,601,000-453,040,000-267,786,000-237,867,084-239,572,000-212,282,666-194,319,000-256,611,166-252,498,668-138,488,000
EBT Margin100.0%--1.77-2.06-3.01-2.90-3.23-4.87-4.94-6.18-7.46-5.49-6.20-8.34-8.98-15.02-13.07-37.26-
Net Income4.2%-392,998,000-410,036,000-443,286,000-593,342,000-528,564,000-553,955,000-704,471,000-569,193,000-536,522,000-453,827,000-268,905,000-238,788,330-240,414,000-213,046,666-195,071,000-257,448,144-253,429,608-139,075,000
Net Income Margin100.0%--1.77-2.06-3.02-2.90-3.24-4.88-4.94-6.18-7.46-5.49-6.20-8.35-8.99-15.02-13.08-37.05-
Free Cashflow100.0%--368,157,000-392,227,000-437,894,000-472,046,000-493,213,000-567,526,000-457,787,000-373,558,000-356,484,000-226,185,000-218,357,656-203,407,000-200,892,000-197,046,000-225,470,672-179,011,968-107,553,027
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q22019Q42019Q32018Q42017Q42016Q4
Assets-5.4%1,1061,1701,2201,2991,4191,5011,6101,7281,8951,1311,29854835539230225089.00
  Current Assets-5.1%1,0181,0721,1241,2101,3361,3931,5011,6191,8091,0491,21648529232926923184.00
    Cash Equivalents-2.4%8598801,0081,1196818479641,3981,7671,01344225976.0069.0063.0023084.00
  Inventory-5.3%36.0038.0032.0029.0023.0020.0019.0012.0011.0013.0013.007.006.001.000.00--
  Net PPE-3.3%56.0058.0058.0051.0046.0045.0043.0037.0032.0029.0029.0021.0021.0020.0020.0012.001.00
Liabilities3.1%17416917519320719323014022412212883.0060.0055.0051.0014.006.00
  Current Liabilities7.1%13312514015616915519311219493.0098.0057.0047.0041.0049.0012.005.00
  Short Term Borrowings------------4.006.006.004.00--
Shareholder's Equity-6.9%9321,0011,0461,1061,2121,3081,3801,5881,6721,0101,169465295337251235-
  Retained Earnings-6.3%-2,031-1,910-1,861-1,799-1,638-1,500-1,418-1,206-1,109-946-713-573-444-398-249-110-60.17
  Additional Paid-In Capital0.7%2,9322,9112,8932,8772,8572,8392,8262,8132,7991,9681,8971,0327357284983459.00
Shares Outstanding0.5%96996496096095895595595093088488.0074.0064.0068.0053.0022.009.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q42018Q32017Q42016Q4
Cashflow From Operations-3.9%-363-349-367-411-445-466-549-440-359-345-216-211-200-196-191-224-178-97.54-70.54-32.37-32.16
  Share Based Compensation9.6%72.0066.0061.0058.0050.0046.0041.0033.0029.0026.0025.0026.0024.0023.0020.0019.0017.0012.0011.0010.005.00
Cashflow From Investing39.5%553396420143-631-522250731190138-554-70585.00187-14.8983.00-0.54-212-283-10.43-2.73
Cashflow From Financing17.1%-4.87-5.87-1.73-1.81-2.998218209281,6728531,1321,0252833752195.007.00144190188106

ZLAB Income Statement

2023-06-30
Unaudited Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Product revenue, net$ 68,864,000$ 47,575,000$ 131,661,000$ 93,670,000
Collaboration revenue0601,00001,230,000
Total revenues68,864,00048,176,000131,661,00094,900,000
Expenses:    
Cost of sales(23,763,000)(17,407,000)(45,100,000)(33,051,000)
Research and development(76,682,000)(66,084,000)(125,153,000)(119,938,000)
Selling, general, and administrative(67,920,000)(63,401,000)(130,430,000)(120,392,000)
Gain on sale of intellectual property10,000,000010,000,0000
Loss from operations(89,501,000)(98,716,000)(159,022,000)(178,481,000)
Interest income10,090,0001,175,00020,321,0001,363,000
Foreign currency loss(40,079,000)(34,895,000)(31,167,000)(32,610,000)
Other expense, net(1,405,000)(5,497,000)(171,000)(10,378,000)
Loss before income tax and share of loss from equity method investment(120,895,000)(137,933,000)(170,039,000)(220,106,000)
Income tax expense0000
Share of loss from equity method investment000(221,000)
Net loss(120,895,000)(137,933,000)(170,039,000)(220,327,000)
Net loss attributable to ordinary shareholders - basic(120,895,000)(137,933,000)(170,039,000)(220,327,000)
Net loss attributable to ordinary shareholders - diluted$ (120,895,000)$ (137,933,000)$ (170,039,000)$ (220,327,000)
Loss per share/ADS - basic (in dollars per share)$ (0.13)$ (0.14)$ (0.18)$ (0.23)
Loss per share/ADS - diluted (in dollars per share)$ (0.13)$ (0.14)$ (0.18)$ (0.23)
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares)964,817,310957,684,820963,140,360956,603,250
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares)964,817,310957,684,820963,140,360956,603,250
American Depositary Shares    
Expenses:    
Loss per share/ADS - basic (in dollars per share)$ (1.25)$ (1.44)$ (1.77)$ (2.30)
Loss per share/ADS - diluted (in dollars per share)$ (1.25)$ (1.44)$ (1.77)$ (2.30)
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares)96,481,73195,768,48296,314,03695,660,325
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares)96,481,73195,768,48296,314,03695,660,325

ZLAB Balance Sheet

2023-06-30
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 859,155$ 1,008,470
Short-term investments15,5000
Accounts receivable (net of allowance for credit loss of $14 and $11 as of June 30, 2023 and December 31, 2022, respectively)47,28339,963
Notes receivable20,7818,608
Inventories, net36,35331,621
Prepayments and other current assets38,43335,674
Total current assets1,017,5051,124,336
Restricted cash, non-current1,791803
Long term investments5,1286,431
Prepayments for equipment6651,396
Property and equipment, net56,41057,863
Operating lease right-of-use assets18,53719,512
Land use rights, net3,0676,892
Intangible assets, net1,6901,511
Long-term deposits1,5801,396
Total assets1,106,3731,220,140
Current liabilities:  
Accounts payable67,03165,974
Current operating lease liabilities7,2997,050
Other current liabilities59,02466,818
Total current liabilities133,354139,842
Deferred income28,62521,360
Non-current operating lease liabilities11,75513,343
Other non-current liabilities3250
Total liabilities174,059174,545
Commitments and contingencies (Note 15)
Shareholders’ equity  
Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 973,355,390 and 962,455,850 shares issued as of June 30, 2023 and December 31, 2022, respectively; 968,566,280 and 960,219,570 shares outstanding as of June 30, 2023 and December 31, 2022, respectively)66
Additional paid-in capital2,932,0532,893,120
Accumulated deficit(2,031,399)(1,861,360)
Accumulated other comprehensive income52,18025,685
Treasury Stock (at cost, 4,789,110 and 2,236,280 shares as of June 30, 2023 and December 31, 2022, respectively)(20,526)(11,856)
Total shareholders’ equity932,3141,045,595
Total liabilities and shareholders’ equity$ 1,106,373$ 1,220,140

About Zai Lab

Ying Du
1950
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.